These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37814347)

  • 1. Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders.
    Bräuer S; Rossi M; Sajapin J; Henle T; Gasser T; Parchi P; Brockmann K; Falkenburger BH
    Acta Neuropathol Commun; 2023 Oct; 11(1):162. PubMed ID: 37814347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies.
    Bargar C; Wang W; Gunzler SA; LeFevre A; Wang Z; Lerner AJ; Singh N; Tatsuoka C; Appleby B; Zhu X; Xu R; Haroutunian V; Zou WQ; Ma J; Chen SG
    Acta Neuropathol Commun; 2021 Apr; 9(1):62. PubMed ID: 33827706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prominent astrocytic alpha-synuclein pathology with unique post-translational modification signatures unveiled across Lewy body disorders.
    Altay MF; Liu AKL; Holton JL; Parkkinen L; Lashuel HA
    Acta Neuropathol Commun; 2022 Nov; 10(1):163. PubMed ID: 36371251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of alpha-synuclein aggregates in gastrointestinal biopsies by protein misfolding cyclic amplification.
    Fenyi A; Leclair-Visonneau L; Clairembault T; Coron E; Neunlist M; Melki R; Derkinderen P; Bousset L
    Neurobiol Dis; 2019 Sep; 129():38-43. PubMed ID: 31078683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
    Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
    Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies.
    Koss DJ; Erskine D; Porter A; Palmoski P; Menon H; Todd OGJ; Leite M; Attems J; Outeiro TF
    Acta Neuropathol Commun; 2022 Jul; 10(1):98. PubMed ID: 35794636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.
    Kramer ML; Schulz-Schaeffer WJ
    J Neurosci; 2007 Feb; 27(6):1405-10. PubMed ID: 17287515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
    Poggiolini I; Gupta V; Lawton M; Lee S; El-Turabi A; Querejeta-Coma A; Trenkwalder C; Sixel-Döring F; Foubert-Samier A; Pavy-Le Traon A; Plazzi G; Biscarini F; Montplaisir J; Gagnon JF; Postuma RB; Antelmi E; Meissner WG; Mollenhauer B; Ben-Shlomo Y; Hu MT; Parkkinen L
    Brain; 2022 Apr; 145(2):584-595. PubMed ID: 34894214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC.
    Groveman BR; Orrù CD; Hughson AG; Raymond LD; Zanusso G; Ghetti B; Campbell KJ; Safar J; Galasko D; Caughey B
    Acta Neuropathol Commun; 2018 Feb; 6(1):7. PubMed ID: 29422107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein.
    Landeck N; Hall H; Ardah MT; Majbour NK; El-Agnaf OM; Halliday G; Kirik D
    Mol Neurodegener; 2016 Aug; 11(1):61. PubMed ID: 27549140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
    Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
    Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluid and Biopsy Based Biomarkers in Parkinson's Disease.
    Coughlin DG; Irwin DJ
    Neurotherapeutics; 2023 Jul; 20(4):932-954. PubMed ID: 37138160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.
    Adler CH; Beach TG; Zhang N; Shill HA; Driver-Dunckley E; Caviness JN; Mehta SH; Sabbagh MN; Serrano GE; Sue LI; Belden CM; Powell J; Jacobson SA; Zamrini E; Shprecher D; Davis KJ; Dugger BN; Hentz JG
    J Neuropathol Exp Neurol; 2019 Oct; 78(10):891-899. PubMed ID: 31504679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
    Peelaerts W; Bousset L; Baekelandt V; Melki R
    Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effects of Lewy body pathology in cognitively impaired individuals.
    Quadalti C; Palmqvist S; Hall S; Rossi M; Mammana A; Janelidze S; Dellavalle S; Mattsson-Carlgren N; Baiardi S; Stomrud E; Hansson O; Parchi P
    Nat Med; 2023 Aug; 29(8):1964-1970. PubMed ID: 37464058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naturally occurring antibodies isolated from PD patients inhibit synuclein seeding in vitro and recognize Lewy pathology.
    Li X; Koudstaal W; Fletcher L; Costa M; van Winsen M; Siregar B; Inganäs H; Kim J; Keogh E; Macedo J; Holland T; Perry S; Bard F; Hoozemans JJ; Goudsmit J; Apetri A; Pascual G
    Acta Neuropathol; 2019 May; 137(5):825-836. PubMed ID: 30805666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
    Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.